Novo Nordisk CagriSema beats tirzepatide on weight loss in Phase 3
Novo Nordisk has reported topline data from two Phase 3 trials of CagriSema, its fixed-dose combination of the amylin receptor agonist cagrilintide and GLP-1 receptor agonist semaglutide, showing superior weight reduction against tirzepatide in type 2 diabetes and a 21% loss against placebo in people with overweight or obesity.
The results were disclosed at Novo's Capital Markets Day on 21 September 2026. In REIMAGINE 5, adults with type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor or both received once-weekly CagriSema 1.0 mg/1.0 mg or tirzepatide 5 mg. At week 60, CagriSema produced an estimated average weight reduction of 12.4% against 9.1% for tirzepatide, meeting the primary superiority endpoint. HbA1c reduction was 1.71% for CagriSema versus 1.67% for tirzepatide, meeting the non-inferiority threshold. In REDEFINE 9, which tested CagriSema as an adjunct to diet and exercise in people with overweight or obesity, the 1.0 mg/1.0 mg dose produced a 21.0% reduction in body weight at week 68 versus 2.0% for placebo, also meeting its primary endpoint.
Clinical significance
Martin Holst Lange, executive vice president for research and development and chief scientific officer at Novo Nordisk, said the findings "demonstrate the strong potency of the combination of semaglutide and cagrilintide" and add to the evidence base for amylin biology as a therapeutic target. He noted that CagriSema remains investigational but said the data strengthen the company's confidence in the asset's potential across both obesity and type 2 diabetes.
The comparison with tirzepatide is of direct commercial interest. Tirzepatide, marketed by Eli Lilly as Mounjaro for type 2 diabetes and Zepbound for obesity, has been one of the most closely watched products in the GLP-1 and incretin space. Critically, the REIMAGINE 5 comparison pits CagriSema 1.0 mg/1.0 mg against tirzepatide 5 mg, which is the starting dose rather than the approved maximum of 15 mg. Novo acknowledged in its release that not all patients in clinical practice reach or tolerate the highest available doses, framing dose flexibility as a meaningful practical advantage for CagriSema.
Regulatory and competitive backdrop
Novo filed a New Drug Application with the US Food and Drug Administration for CagriSema in weight management in December 2025 and expects an agency decision in Q4 2026. If approved on schedule, CagriSema would enter a market that already includes semaglutide's own branded forms, Ozempic and Wegovy, as well as tirzepatide, creating an unusual situation in which Novo would be competing with itself across two product lines. The company's strategic rationale appears to rest on CagriSema serving patients who need greater efficacy or who cannot tolerate or sustain higher doses of existing agents.
The broader GLP-1 and amylin segment is attracting significant investment and pipeline activity. Several biotech companies and larger pharmaceutical groups are pursuing next-generation incretin combinations, oral formulations and once-monthly dosing schedules. The REIMAGINE and REDEFINE programme data add weight to Novo's position at the front of that field, but investors will want to see head-to-head data at equivalent or higher tirzepatide doses before drawing firm conclusions about CagriSema's differentiation in a regulatory filing context.
Novo also mentioned, without detail, promising results for CagriSema in painful diabetic neuropathy, indicating potential label expansion ambitions beyond weight and glycaemic control. Full data on that indication are expected to be disclosed at a future date. The next near-term milestone remains the FDA decision on the weight-management NDA, anticipated before the end of 2026.